Covid Vaccines: Intellectual Property and Access, a Melting Pot of Viewpoints

Innovation Council member SARIMA has published an article by Dr Andrew Bailey, in which he explains the various views on the issue of access to IP in light of the COVID-19 pandemic. He sees a need for governments to build capacity in the manufacture of vaccines, in order to both meet local demand and assist with pandemic response. 

During the pandemic, there was incredible collaboration across institutional, corporate, and national boundaries to address the urgent health crisis. Bailey hopes that this experience will shape global thinking about collaboration, and about how to ensure equitable access to healthcare whilst taking care to properly respect the infrastructural investments, trade secrets, and know-how of manufacturers.